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SUMMARY
Chronic myeloid leukemia (CML) is induced by BCR-ABL1 and can be effectively treated for many years
with Imatinib until leukemia cells acquire drug resistance through BCR-ABL1 mutations and progress into
fatal B lymphoid blast crisis (LBC). Despite its clinical significance, the mechanism of progression into
LBC is unknown. Here, we show that LBC but not CML cells express the B cell-specific mutator enzyme
AID. We demonstrate that AID expression in CML cells promotes overall genetic instability by hypermutation
of tumor suppressor and DNA repair genes. Importantly, our data uncover a causative role of AID activity in
the acquisition ofBCR-ABL1mutations leading to Imatinib resistance, thus providing a rationale for the rapid
development of drug resistance and blast crisis progression.INTRODUCTION
Activation-induced cytidine deaminase (AID) promotes somatic
hypermutation and class switch recombination of immunoglob-
ulin (Ig) genes in germinal center (GC) B cells (Muramatsu
et al., 2000; Revy et al., 2000). AID initiates both processes by
deaminating Ig gene cytidines into uracils, thereby creating
DNA mismatches that are ultimately processed into mutations
or DNA breaks (Chaudhuri et al., 2003; Dickerson et al., 2003;
Petersen-Mahrt et al., 2002). Although AID primarily acts on Ig232 Cancer Cell 16, 232–245, September 8, 2009 ª2009 Elsevier Incvariable and switch regions, non-Ig genes, including BCL6,
CD79A, CD79B, CD83, and PAX5, are occasionally targeted
by hypermutation in GC B cells (Shen et al., 1998; Liu et al.,
2008). AID off-target activity has been implicated in malignant
transformation of GC-derived B cell lymphomas and plasmacy-
tomas (Ramiro et al., 2006; Pasqualucci et al., 2008; Takizawa
et al., 2008; Chesi et al., 2008; Robbiani et al., 2008). Additional
studies suggest that AID, together with RAG1/RAG2 enzymes,
may also contribute to chromosomal translocations at early
stages of B cell development (Tsai et al., 2008).SIGNIFICANCE
Treatment of patients with CML in chronic phase with the BCR-ABL1 kinase inhibitor Imatinib leads to a 5 year overall
survival of 95%. Upon blast crisis progression, however, median overall survival decreases to less than seven months,
and CML blasts are frequently Imatinib resistant because of BCR-ABL1 mutations. Here, we show that PAX5-mediated B
cell lineage conversion of CML cells results in transcription of AID, a B cell-specific enzyme that hypermutates immunoglob-
ulin and other genes in germinal center B cells. In CML cells, AID promotes widespread hypermutation, B lymphoid blast
crisis progression, BCR-ABL1 mutation, and the acquisition of Imatinib resistance. Our studies shed light on the origin of
CML-LBC and identify AID as a potential pharmacological target to suppress fatal blast crisis transformation..
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AID-Induced Blast Crisis Progression in CMLUnder physiological circumstances, AID gene expression is
induced in mature germinal center or activated B cells by
cross-linking of the B cell receptor, CD40, IL4R, and Toll-like
receptors (Crouch et al., 2007; Muramatsu et al., 1999). Down-
stream activation of NF-kB, along with B cell-specific transcrip-
tion factors PAX5 and E2A, is required for transcriptional activa-
tion of AID (Gonda et al., 2003; Sayegh et al., 2003; Dedeoglu
et al., 2004; Gourzi et al., 2007; see Table S1 available with this
article online). We have recently demonstrated that oncogenic
BCR-ABL1 kinase activity in acute lymphoblastic leukemia with
Philaldelphia chromosome (Ph+ ALL) induces aberrant AID
expression (Feldhahn et al., 2007). As in germinal centers, AID
in Ph+ ALL cells is enzymatically active and can hypermutate
BCL6 and Ig genes (Feldhahn et al., 2007). However, whether
AID plays a role in malignant progression of Ph+ ALL or other
BCR-ABL1 leukemias remains unclear.
Chronic myeloid leukemia (CML), first identified in 1845
(Virchow, 1845), is—like Ph+ ALL—characterized by the Phila-
delphia chromosome encoding BCR-ABL1 (Rowley, 1973).
CML develops from a hematopoietic stem cell and consequently
displays multilineage differentiation potential (Calabretta and
Perrotti, 2004). If not efficiently treated, CML follows a triphasic
clinical course with an initial indolent chronic phase (CML-CP;
5–15 years) followed by an intermediate accelerated phase
and eventually a blast crisis of myeloid (CML-MBC; 60% inci-
dence), B lymphoid (CML-LBC; 30% incidence), or biphenotypic
myeloid/lymphoid (10% incidence) lineage (Calabretta and
Perrotti, 2004). Although CML-CP can be effectively treated
with Imatinib for many years (Druker et al., 2006), CML-LBC is
invariably multidrug resistant and fatal within weeks or months
(Druker et al., 2001). The molecular basis of chronic phase to
blast crisis transformation is still largely unknown. However,
the majority of patients in blast crisis acquire secondary muta-
tions or deletions at ARF, MYC, RB1, AML1, TP53, and RAS
genes (Melo and Barnes, 2007), which are believed to accelerate
disease progression.
In addition, blast crisis progression correlates with acquisition
of mutations in theBCR-ABL1 kinase, which confer resistance to
Imatinib: The frequency of such mutations is at least six times
higher in blast crisis CML than in chronic phase CML (Soverini
et al., 2006; Table S1). In a number of patients,BCR-ABL1 kinase
mutations can be found even prior to treatment with Imatinib
(Pfeifer et al., 2007). Despite their clinical significance, the mech-
anisms responsible for Imatinib resistance and genetic instability
in CML remain unresolved. We here investigate the hypothesis
that aberrant AID expression contributes to widespread genomic
instability, Imatinib resistance, and B lymphoid blast crisis
progression of CML.
RESULTS
To determine whether AID is implicated in CML progression into
fatal blast crisis, we examined AID expression in patients with
coexisting chronic phase CML (CML-CP) and B lymphoid blast
crisis CML (CML-LBC). Leukemia cells of either phenotype
were clearly distinguished in bone marrow samples from these
patients on the basis of myeloid (CP; CD13+CD19 CD34+)
and B lymphoid (LBC; CD13CD19+CD34+) markers. Real-time
RT-PCR showed significant expression of AID mRNA in CML-CaLBC blasts, but little or no expression in CML-CP cells (6–10
fold difference; p = 0.013; Figure 1A). By comparison, AID
expression in primary LBC blasts was 5–10 fold lower relative
to germinal center (GC) B cells isolated from human tonsils
(Figure 1A). Western blot analysis also showed AID protein
present in LBC but absent in CML-CP cells (Figure 1B). Signifi-
cantly, AID was in all cases coexpressed with the B cell
lineage-inducer PAX5 (Nutt et al., 1999), which has been shown
to promote AID gene transcription (Gonda et al., 2003; Sayegh
et al., 2003; Figure 1C). To measure AID protein expression on
a per cell basis, we performed intracellular staining with an
AID-specific antibody. Compared with GC-derived diffuse-large
B cell lymphoma cells (DLBCL) that express high levels of AID
(Lenz et al., 2007), AID protein was undetectable in bone marrow
samples from patients with myeloid CML-CP (Figure 1D). In
contrast, patients with early CML-LBC harbored cells expressing
AID at varying levels (3%–18%) along with the B cell antigen
CD19 (Figure 1D). Surface expression of the hematopoietic
progenitor cell antigen CD34 on these cells excluded the possi-
bility of sample contamination with mature, AID+-activated B
cells. We conclude that progression of CML-CP into CML-LBC
is characterized by aberrant expression of PAX5 and its tran-
scriptional target AID.
We next examined BCR-ABL1-mediated transformation of
bone marrow cells from mice carrying anAID-GFP reporter trans-
gene (Crouch et al., 2007). Isolated bone marrow cells from
AID-GFP animals were transduced with a retrovirus expressing
humanBCR-ABL1 (Pear et al., 1998), or a retroviral empty vector
control (MSCV). Following transduction, cells were cultured on
bone marrow stroma in the presence of either myeloid (IL3, IL6,
and SCF) or B lymphoid (IL7) growth factors following classical
models of myeloid CML and B lymphoid LBC/Ph+ ALL, respec-
tively (Li et al., 1999). Under myeloid culture conditions, neither
normal nor BCR-ABL1-transformed myeloid progenitor cells
displayed AID-GFP reporter expression (Figure 1E). In contrast,
5% of the BCR-ABL1-transformed B lymphoid progenitors
exhibited strongAID-GFP (Figure 1E). In agreement with previous
findings (Gourzi et al., 2006), retroviral infection with empty vector
control also induced AID-GFP fluorescence in a small number of
B lymphoid progenitor cells (0.7%; Figure 1E). Of note, AID
expression inBCR-ABL1AID-GFP+ leukemia cells was commen-
surate to splenic B cells activated with LPS and IL4, about 240-
fold higher than in AID-GFP counterparts (Figure 1F).
To further characterize AID+ B lymphoid leukemias, we
analyzed AID-GFP+ and AID-GFP cells among BCR-ABL1-
transformed B lymphoid leukemia and LPS/IL4-activated splenic
B cells with Affymetrix 430 GeneChips (Figure 2). A number of
genes typically coexpressed with AID in activated B cells were
also up-regulated in BCR-ABL1 leukemias (Mfap5, Iigp1,
Rcan2, Ccl25, Pim2, Tlr7, and Ilr2a; Figure 2A). Conversely, a
subset of DNA repair genes was strongly up-regulated with
AID in activated splenic B cells but absent in BCR-ABL1
leukemia cells (Figure 2B). Among these, Brca1, FancD2, and
Rad51 (Longerich et al., 2008); Atm and Cdkn2a (Ramiro et al.,
2006); and Chek1 (Gourzi et al., 2006) have been previously
implicated either in the repair of AID-induced DNA lesions or
negative regulation of AID-induced chromosomal translocation
events. Thus, BCR-ABL1-transformed B lymphoid leukemia
cells express AID in the absence of the DNA repair mechanismsncer Cell 16, 232–245, September 8, 2009 ª2009 Elsevier Inc. 233
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AID-Induced Blast Crisis Progression in CMLFigure 1. B Cell Lineage-Specific Activation of AID in BCR-ABL1-Transformed Leukemia Cells
(A) Quantitative RT-PCR analysis of AID mRNA expression in CD13 CD19+ B lymphoid (CML-LBC) and CD13+ CD19 myeloid (CML-CP) bone marrow cells
sorted from four patients (I–IV) with early B lymphoid blast crisis CML. Peripheral blood naive (IgD+) and germinal center (GC) B cells were used as negative
and positive controls, respectively. AID mRNA levels (means ± SD) were normalized according to COX6B transcripts.
(B) AID protein levels in CML-LBC and CML-CP cells from two patients (I and II) were compared with those of tonsillar GC B cells by Western blotting using EIF4E
as loading control.
(C) PAX5 mRNA levels in sorted CML-CP and CML-LBC cells were measured by quantitative RT-PCR (means ± SD).
(D) AID protein expression in chronic phase and lymphoid blast crisis CML cells (I–IV) was measured by flow cytometry (intracellular staining) using diffuse large B
cell lymphoma (DLBCL) cells as control.
(E) Bone marrow cells from AID-GFP reporter transgenic mice were transduced withBCR-ABL1 or empty vector control and cultured under myeloid (IL3, IL6, and
SCF) or B lymphoid (IL7) growth conditions.
(F) AID mRNA levels (means ± SD) in sorted GFP (gray) and GFP+ (green) cell populations from LPS/IL4-stimulated splenic B cells or BCR-ABL1-transformed
leukemia cells from AID-GFP transgenic mice were measured by quantitative RT-PCR.that typically safeguard genome integrity during normal B cell
activation in GCs.
In addition to DNA repair molecules, the micro RNA miR-155
acts as a tumor suppressor by protecting B cells from AID-
induced chromosomal translocations (Dorsett et al., 2008).
This mechanism relies on the ability of mir-155 to negatively
regulate AID protein levels and to curb excessive AID activity
during B cell activation in GCs (Teng et al., 2008). Deep
sequencing analysis of human GC B cells and mouse activated
B cells confirmed that expression of AID in these cells is matched
by high levels of miR-155 expression (Figures 2C and 2D). In
contrast, human B lymphoid CML-LBC and mouse B lymphoid
BCR-ABL1 leukemia cells expressed high levels of AID in the
absence of miR-155 (Figures 2C and 2D). Hence, although AID
is readily expressed in B lymphoid CML-LBC, some of the mech-
anisms that normally constrain AID-mediated genetic instability
are not concurrently induced.
To determine whether AID is functional in human CML-LBC, we
next assessed somatic hypermutation of immunoglobulin heavy
chain (IGHM), BCL6, and MYC genes, which are targeted by234 Cancer Cell 16, 232–245, September 8, 2009 ª2009 Elsevier InAID in germinal center B cells (Shen et al., 1998; Liu et al., 2008;
for a schematic of regions selected for sequence analysis, see
Figures S1A–S1C). In contrast to AID-negative CML-CP cells,
AID+ CML-LBC cells carried mutations in IGHM, BCL6, and
MYC at frequencies comparable to those previously reported
for GC B cell-derived lymphoma (Pasqualucci et al., 2001;
Figure 3A). To determine whether AID promotes overall genetic
instability inBCR-ABL1 tumors, we measured gene copy number
alterations (i.e., deletions or amplifications) in 23 primary cases of
Ph+ ALL using a 250K NspI SNP array (Figure 3B). On the basis of
AID mRNA levels, Ph+ ALL samples were classified as either
AIDhigh (16 cases) or AIDlow (7 cases). SNP analysis revealed
a higher frequency of gene copy number alterations in the AIDhigh
as compared to the AIDlow group (median 14 [range 6–50] versus
median 5 [range 2–8]; p = 0.02; Figure 3B). Notably, deletion
frequencies at the tumor suppressor genes ARF (CDKN2A) and
INK4B (CDKN2B) at 9p21 were considerably higher in the pres-
ence of AID (p = 0.04; Figure 3B).
Deletion of ARF has previously been implicated in the progres-
sion of myeloid CML-CP into B lymphoid CML-LBC (Calabrettac.
Cancer Cell
AID-Induced Blast Crisis Progression in CMLFigure 2. BCR-ABL1-Transformed B Lym-
phoid Leukemia Cells Express AID in the
Absence of Protective Mechanisms to
Maintain Genome Integrity
Bone marrow cells and splenic B cells were iso-
lated from Aid-GFP reporter transgenic mice.
Bone marrow B cell precursors were transformed
with retroviral BCR-ABL1, and splenic B cells
were activated by LPS and IL4. From BCR-
ABL1-transformed leukemia cells and LPS/IL4-
activated B cells, Aid-GFP+ and Aid-GFP cells
were sorted and subjected to RNA isolation and
microarray analysis using the 430 GeneChip plat-
form (GEO accession number GSE13611). For
both cell types, genes that were differentially
expressed between Aid-GFP+ and Aid-GFP pop-
ulations were identified and sorted according to
the ratio of gene expression values in Aid-GFP+
and Aid-GFP populations fromBCR-ABL1-trans-
formed leukemia cells (A) and LPS/IL4-activated B
cells (B). Genes that are concordantly up-regu-
lated with AID expression both in BCR-ABL1
leukemia (A) and activated splenic B cells (B) are
highlighted in bold type. Genes related to DNA
damage and repair and chromosomal stability
are highlighted in red. In (C) and (D), AID mRNA
levels (percentage of reference gene [means ±
SD] as determined by quantitative RT-PCR) were
plotted against expression levels of miR-155
(microRNA tags per million, as determined by Illu-
mina deep sequencing). To this end, Aid mRNA
and mmu-miR-155 levels were measured in
murine LPS/IL4-activated splenic B cells and
mouse bone marrow B cell precursors that were
transformed by BCR-ABL1 (C). Likewise, AID
mRNA and hsa-miR-155 levels were measured in
sorted human tonsillar germinal center B cells
(GCB; CD77highCD38+IgD) and human B
lymphoid CML-LBC cells (D).and Perrotti, 2004). To determine whether AID directly targets
ARF in LBC cells, we assayed this locus by ligation-mediated
PCR for the presence of ssDNA breaks, which are intermediates
of AID-mediated hypermutation (Unniraman and Schatz, 2007).
We found evidence of ssDNA breaks at the ARF locus of sorted
AID+ LBC cells, whereas these lesions were absent in AIDCML-
CP cells isolated from the same patients (Figure 3C), indicating
that ARF is a potential AID target in LBC cells. In support of
this view, the CDKN2A (ARF) gene promoter carries five E box
motifs (CAGGTG). E box motifs are tightly associated with AID
hypermutation activity at Ig and non-Ig genes alike (Michael
et al., 2003). In addition, analysis of a database of published
ARF mutations in B lymphoid Ph+ ALL and CML-LBC revealed
a significant preference for mutations at RGYW or WRCY DNA
motifs (13 of 60 mutations [21.7%]; p < 0.05), which are hotspots
for AID-induced hypermutation (Do¨rner et al., 1997). No such
preference was observed in nonlymphoid tumors (24 of 461
mutations [5.2%]; p > 0.22; Figure S2). These observations
suggest that AID promotes genetic instability in CML-LBC via
widespread somatic hypermutation. To further explore this
idea, we transformed bone marrow B cell precursors from
AID/ and AID+/+ mice with BCR-ABL1-expressing retrovi-
ruses. After 9 weeks in cell culture, we assessed genomic dele-
tions and amplifications by comparative genomic hybridizationC(CGH). The frequency of copy number alterations was signifi-
cantly higher in AID+/+ B lymphoid leukemia cells (52 ± 12),
compared with their AID/ counterparts (20.6 ± 2.1; p = 0.02;
Figure 3D). Of note, 22 genes were consistently deleted in the
presence but not in the absence of AID (Figure 3E). Among these,
we found examples of genes implicated in the DNA repair and/or
DNA damage response. Deletions of the Msh3, Ddi2, and
Ctnnd2 genes were recurrently found in AID+/+ but not AID/
B lymphoid BCR-ABL1 leukemias (Figure 3E), suggesting that
AID promotes genetic instability in BCR-ABL1 lymphoid leuke-
mias in part via hypermutation of DNA repair and DNA damage
response genes.
Acquisition ofBCR-ABL1 kinase domain mutations represents
a critical event in the progression of CML-CP into fatal CML-
LBC, as they often confer resistance to Imatinib treatment
(Shah et al., 2002). To investigate a potential role of AID in this
process, we amplified and sequenced the BCR-ABL1 kinase
domain from single AID-negative myeloid and AID+ B lymphoid
CML cells isolated from four patients with early CML-LBC under-
going Imatinib treatment. Single-cell PCR analysis and direct
sequencing revealed the presence of L248V and T315I muta-
tions in a significant fraction of B lymphoid but not myeloid
CML cells in three of the patients (Figure 4A). The fourth patient
showed positive PCR products in only a few sorted B lymphoidancer Cell 16, 232–245, September 8, 2009 ª2009 Elsevier Inc. 235
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AID-Induced Blast Crisis Progression in CMLFigure 3. Evidence of Aberrant AID Activity in B Lymphoid BCR-ABL1 Leukemias
(A) CML-LBC (CD13 CD19+ CD34+) and CML-CP (CD13+CD19 CD34+) cells were sorted from four patients and analyzed for somatic mutations within rear-
ranged IGHM loci, as well as BCL6 and MYC genes (means of mutation frequencies ± SD). Mutation frequencies in naive (IgD+) and germinal center (GC) B cells,
as well as DLBCL cells, were studied as a reference. CML-CP cells carry IGHM loci in germline configuration, which precludes mutation analysis.
(B) SNP mapping analysis was performed for 23 bone marrow samples from patients with B lymphoid Ph+ ALL (GEO accession number GSE13612). Samples
were selected on the basis of particularly high (n = 16; AIDhigh) or low (n = 7; AIDlow) AID mRNA levels. Deletions or duplications of gene loci are represented in
green or red, respectively, with color intensities reflecting the frequency of these lesions based on the total number of samples analyzed.
(C) Short-lived DNA single-strand break (SSB) intermediates were determined at the ARF and IGHM loci by ligation-mediated PCR (LM-PCR) in LBC and
CML-CP, as well as in germinal center B cells (GC). The presence of ARF and rearranged VH-DJH genes was verified by genomic PCR in each sample.
(D) Gene copy number alterations (CNA) were studied in BCR-ABL1-transformed bone marrow B cell precursors from AID/ and AID+/+ mice by comparative
genomic hybridization (means of CNA frequencies ± SD; GEO accession number GSE15093) using genomic DNA from normal splenic B cells as a reference.
AID-specific lesions were identified in three CGH experiments comparing AID+/+ BCR-ABL1 leukemia cells with AID/ BCR-ABL1 leukemia.
(E) Data for all genes/loci where a copy number change between AID/ and AID+/+ BCR-ABL1 leukemia was found in at least one experiment (sorted by
chromosomal localization, chromosomes 1 through 19; recurrent deletions (green) or amplifications (red) are highlighted.CML cells. However, the E255K mutation was repeatedly ampli-
fied from bulk CML-LBC cells, whereas myeloid cells from the
same patient were unmutated (data not shown). Since these
findings show a straight correlation between AID expression
and the acquisition of clinically relevant BCR-ABL1 mutations
in CML-LBC, we investigated whether enforced AID expression
can induce BCR-ABL1 mutations in CML. To this end, we trans-
duced eight AID-negative myeloid CML cell lines with a retroviral
vector encoding AID/GFP or GFP alone (Figure S3). Transduced
cells were cultured in the presence or absence of Imatinib for
3 weeks, and the relative enrichment or depletion of GFP+ cells
was monitored by flow cytometry. Although GFP+/GFP ratios
were unchanged in untreated cultures, we observed a preferen-
tial expansion of AID-GFP transduced CML cells in the presence
of Imatinib (Figure 4B). Importantly, single-cell PCR analysis
consistently showed the presence of clinically relevant BCR-236 Cancer Cell 16, 232–245, September 8, 2009 ª2009 Elsevier IncABL1 kinase mutations in Imatinib-treated AID/GFP+ but not
GFP+ CML cells (Table 1). These results were confirmed in a
complementary assay based on enzymatic digestion of BCR-
ABL1 kinase amplification products (Figure S4). We conclude
that enforced AID expression can promote mutagenesis of the
BCR-ABL1 oncogene in CML cells. To examine whether this
activity leads to Imatinib resistance in vivo, we then labeled
GFP+ and AID/GFP+ transduced CML cells with lentiviral firefly
luciferase and injected them intrafemorally into sublethally irradi-
ated NOD/SCID mice. Leukemia engraftment was first observed
12 days postinjection (Figure 4C), as determined by biolumines-
cence imaging. When focal expansion of leukemic growth
became evident (day 20), treatment with Imatinib (100 mg/kg
twice daily) was started. By day 35, all 14 mice injected with
AID/GFP-transduced CML cells had developed progressive
disease, as opposed to 5 of 12 GFP control mice (p < 0.02;.
Cancer Cell
AID-Induced Blast Crisis Progression in CMLFigure 4. AID Expression in CML Cells Induces Imatinib Resistance In Vitro and In Vivo
(A) Single CML-CP and LBC cells from three patients (I–III) with early lymphoid blast crisis under Imatinib treatment were sorted into individual PCR tubes and
studied by single-cell PCR. AID mRNA levels (percentage of COX6B mRNA) for each cell population is indicated.
(B) Four AID-negative human myeloid CML cell lines were transduced with retroviral vectors encoding AID-GFP or GFP alone and cultured for 3 weeks in the
presence or absence of 2 mmol/l Imatinib. Relative outgrowth or depletion of GFP+ cells was monitored by flow cytometry (means ± SD).
(C) Firefly luciferase-labeled AID-GFP+ and GFP+ CML cells were intrafemorally injected into sublethally irradiated NOD/SCID recipient mice. Leukemia cell
growth was monitored by bioluminescence imaging at the times indicated.
(D) Overall survival of NOD/SCID mice injected with either AID-GFP+ or GFP+ CML cells and treated with 100 mg/kg/day Imatinib (day 20–40) is depicted by a
Kaplan-Meier analysis.
(E) Bone marrow B cell precursor cells from AID+/+ and AID/ mice were transformed by BCR-ABL1 and cultured for 6 weeks under B lymphoid growth
conditions. Subsequently, AID+/+ and AID/ BCR-ABL1 B lymphoid leukemia cells were treated with gradually increasing concentrations of Imatinib (0.1 to
1.75 mmol/l) for 2 weeks. Surviving cells were subjected to sequence analysis for BCR-ABL1 kinase mutations. Red circles, ABL1 mutations conferring clinical
Imatinib resistance; orange circles, C/T or G/A transitions; gray circles, other mutations.Figure 4C). Correspondingly, all mice injected with AID/GFP+
CML cells were dead at day 54, whereas about half of the mice
injected with GFP+ CML cells were still alive 162 days postinjec-
tion (Figure 4D).
Our transduction studies clearly show that, although not abso-
lutely required, AID can accelerate the acquisition of BCR-ABL1
kinase domain mutations in human CML. To test AID depen-
dence of these mutations in a genetic experiment, we trans-
duced bone marrow B cell precursors from AID+/+ and AID/
mice with BCR-ABL1 to generate AID+/+ and AID/ B lymphoid
BCR-ABL1 leukemias. AID+/+ and AID/ B cell precursors
transformed by BCR-ABL1 at a similar efficiency showed similar
leukemic growth kinetics, viability, and colony formation poten-
tial in a methyl-cellulose semisolid culture system (Figure S5).
Six weeks following transformation, AID+/+ and AID/ leukemia
cells were treated with increasing concentrations of ImatinibC(from 0.1 to 1.75 mmol/l) over a period of 2 weeks. Under these
conditions, we observed a reproducible survival advantage of
AID+/+ relative to AID/ leukemia cells (data not shown). Impor-
tantly, sequence analysis of the BCR-ABL1 kinase domain
revealed multiple AID+/+ clones carrying BCR-ABL1 kinase
mutations commonly observed in Imatinib-resistant LBC (Shah
et al., 2002; Table S2; Figure 4E). Conversely, the BCR-ABL1
mutation frequency in AID/ leukemias was within the range
of Pfu DNA polymerase error rate (p = 0.09; Figure 4E). A signif-
icant number of mutations in AID+/+ cells were C/T (e.g., T315I)
or G/A (e.g., E255K) transitions, suggesting that AID could
directly target the BCR-ABL1 fusion gene.
The transcription factor PAX5 regulates both AID-gene
expression (Gonda et al., 2003; Sayegh et al., 2003; Table S1)
and B cell lineage commitment of hematopoietic progenitor cells
(Nutt et al., 1999). To investigate whether ectopic expression ofancer Cell 16, 232–245, September 8, 2009 ª2009 Elsevier Inc. 237
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AID-Induced Blast Crisis Progression in CMLTable 1. Single-Cell RT-PCR Analysis of BCR-ABL1 Kinase Domain Mutations
Cell Type
ABL1 Exons 4–6
Sequence Analysis Cells
C/T or G/A
Transitions
Amino Acid
Change IC50 (mmol/l Imatinib)
EM2-GFP wild-type 12/12
EM2-AID/GFP 742 CTG/GTG 3/10 No L248V 7
944 ACT/ATT 5/10 Yes T315I 16
wild-type 3/10 0.6
JK1-GFP wild type 11/11 0.6
JK1-AID/GFP 742 CTG/GTG 3/10 No L248V 7
835 GAG/GTG 1/10 No Silent 0.6
944 ACT/ATT 2/10 Yes T315I 16
wild-type 4/10 0.6
JURL-GFP wild-type 12/12 0.6
JURL-AID/GFP 742 CTG/GTG 3/10 No L248V 7
764 GAG/AAG 1/10 Yes E255K 12.1
944 ACT/ATT 3/10 Yes T315I 16
wild-type 3/10 0.6
K562-GFP 742 CTG/GTG 3/10 Yes L248V 7
944 ACT/ATT 3/10 Yes T315I 16
wild-type 5/10 0.6
K562-AID/GFP 742 CTG/GTG 3/10 No L248V 7
764 GAG/AAG 1/10 Yes E255K 12.1
819 TTG/TTA 1/10 Yes Silent 0.6
944 ACT/ATT 3/10 Yes T315I 16
wild-type 3/10 0.6
KYO-GFP wild-type 11/11
KYO-AID/GFP 742 CTG/GTG 1/10 No L248V 7
764 GAG/AAG 1/10 Yes E255K 12.1
819 TTG/TTA 1/10 Yes Silent 0.6
944 ACT/ATT 4/10 Yes T315I 16
wild-type 3/10 0.6
LAMA84-GFP wild-type 9/9 0.6
LAMA84-AID/GFP 742 CTG/GTG 9/10 No L248V 7
764 GAG/AAG 1/10 Yes E255K 12.1
837 GAG/GTG 1/10 No E279V 9.9
944 ACT/ATT 4/10 Yes T315I 16
wild-type 2/10 0.6
MEG1-GFP wild-type 11/11 0.6
MEG1-AID/GFP 742 CTG/GTG 3/11 No L248V 7
764 GAG/AAG 1/11 Yes E255K 12.1
819 TTG/TTA 1/11 Yes Silent 0.6
944 ACT/ATT 4/11 Yes T315I 16
wild-type 2/11 0.6
The BCR-ABL1 kinase domain (exons 4–6 of ABL1) was subjected to sequence analysis. To prevent coamplification of normal ABL1 transcripts from
nonrearranged alleles, the first round of PCR used a BCR-forward and an ABL1-reverse primer. The second round of amplification used ABL1 gene-
specific primers (exons 4–6). The rate of Taq DNA polymerase errors was calculated at 83 105/PCR cycle in the first round of PCR amplification. The
CML cell lines K562 carries preexistingBCR-ABL1 kinase mutations (L248V and T315I), which is consistent with Imatinib resistance of these cells in cell
culture (data not shown). IC50 values are derived from publications referenced in Table S2.PAX5 in myeloid CML cells was sufficient to induce AID tran-
scription and B cell lineage conversion, we transduced PAX5-
negative CML cells with a retroviral vector expressing PAX5/
GFP or GFP alone. Enforced expression of PAX5 resulted in238 Cancer Cell 16, 232–245, September 8, 2009 ª2009 Elsevier Incsignificant up-regulation of known B cell-specific PAX5-target
genes, includingAID,SLP65 (BLNK), andCD79A (Iga; Figure 5A).
This was accompanied by surface expression of CD19 in a small
subset of PAX5/GFP+ but not in GFP+ CML cells (Figure 5B)..
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AID-Induced Blast Crisis Progression in CMLFigure 5. Ectopic Expression of PAX5 in CML Cells Induces Partial B Cell Lineage Conversion, AID Expression, and Imatinib Resistance
(A) CML cell lines were transduced with retroviral vectors encoding GFP (green) or PAX5/GFP (red), and expression of B cell lineage specific genes PAX5, AID,
CD79A (Iga) and SLP65 (BLNK) was monitored by quantitative RT-PCR (means ± SD).
(B) FACS analysis of CD19+ subclones emerging from GFP or PAX5/GFP-transduced CML cells cultured in the presence or absence of Imatinib.
(C) Spectratyping analysis of rearranged immunoglobulin heavy chain genes from GFP-transduced (left), PAX5/GFP-transduced CML cells (middle), or primary
CD19+ peripheral blood B cells pooled from four healthy donors (right). The bottom panel shows the sequence analysis of oligoclonal IGHM gene rearrangements
amplified from PAX5/GFP-transduced CML cells.
(D) Four different CML cell lines were transduced with GFP orPAX5/GFP and grown in the presence or absence of rising concentrations of Imatinib (from 0.1 mmol/l
to 1.75 mmol/l) for 16 days. The percentage of GFP+ cells (means ± SD) was monitored over time by flow cytometry.Upon prolonged treatment with Imatinib, CD19+ CML subclones
were positively selected to more than 16% after 6 weeks
(Figure 5B). Furthermore, immunoglobulin spectratyping anal-
ysis of PAX5/GFP-transduced CML cells showed evidence of
PAX5-induced de novo immunoglobulin VH-DJH rearrangement
(Figure 5C), which is consistent with the role of PAX5 at
promoting VH-DJH recombination (Zhang et al., 2006). Sequence
analysis of immunoglobulin gene rearrangements in PAX5/GFP-
transduced CML cells revealed a striking preference for the most
proximal located VH gene segments: among 37 informative
clones, only VH6-1 and VH1-2 gene segments (#1 and #2 most
proximal located among 123 VH segments) were found rear-
ranged. PAX5-induced V(D)J recombination was also aberrant:
instead of an initial DH-JH joint rearranging to different VH-seg-
ments, a preexisting VH-DH joint (VH6-1-DH5-5) was rearranged
to various JH segments (JH4 and JH6; Figure 5C). We conclude
that ectopic expression of PAX5 in myeloid CML cells induces
partial B cell lineage conversion and AID expression.
To determine whether PAX5 can promote Imatinib resistance
in CML, PAX5/GFP+ and GFP+ human leukemia cells were
cultured in the presence of increasing concentrations of Imatinib
(0.1 mmol/l to 1.75 mmol/l). In analogy to results obtained with
AID/GFP (Figure 4B), we observed a time-dependent outgrowthCof PAX5/GFP+ CML cells in the presence of Imatinib (Figure 5D).
Sequence analysis confirmed the presence of mutations within
the BCR-ABL1 kinase domain of PAX5/GFP but not in GFP-
transduced CML cells (Table 2). We conclude that enforced
PAX5 expression in myeloid CML cells can lead to partial B
cell lineage conversion, AID expression, and Imatinib resistance
via BCR-ABL1 mutation.
AID-mediated hypermutation preferentially targets RGYW and
WRCY hotspot motifs (Do¨rner et al., 1997) and displays a bias
toward C/T and G/A transitions over transversion mutations
(Di Noia and Neuberger, 2002; Faili et al., 2002). To explore
whether BCR-ABL1 is a direct target of AID, we assembled
and analyzed a database of 700 published BCR-ABL1 kinase
domain mutations (572 from CML-CP and 128 from CML-LBC/
Ph+ ALL; Figure S6; Table S2). In support of direct AID-mediated
hypermutation of BCR-ABL1, we found the frequency of C/T
and G/A transitions to be notably higher in B lymphoid
CML-LBC/Ph+ ALL (66.4%) relative to CML-CP (19.9%; p < 0.01;
Figure 6B; Table S2). This difference was exemplified by the
763G/A transition leading to E255K, and the 764A/T trans-
version leading to E255V. Both mutations target the same codon
and are associated with a similar degree of Imatinib resistance
(IC50 [Imatinib] at 12.1 mmol/l and 17 mmol/l, respectively). Inancer Cell 16, 232–245, September 8, 2009 ª2009 Elsevier Inc. 239
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Cell Type
CD19+
clones
AID mRNA
(% COX6B)
ABL1 Exons 4–6
Sequence Analysis Clones
Amino Acid
Change
IC50
(mmol/l Imatinib)
KYO-GFP <0.01% <0.01 764 GAG/AAG 1/35 E255K 12.1
wild-type and silent 34/35 0.6
Imatinib-resistant 1/35 (2.9%)
KYO-PAX5/GFP 0.5% 4.24 ± 0.95 742 CTG/GTG 4/48 L248V 7.0
764 GAG/AAG 5/48 E255K 12.1
944 ACT/ATT 16/48 T315I 16
1078 ATC/GTC 2/48 I360V Unknown
1187 CAT/CGT 2/48 H396R 1.8
wild-type and silent 21/48 0.6
Imatinib resistant 27/48 (56%)contrast to E255V, the E255K G/A transition occurs five times
more frequently in CML-LBC/Ph+ ALL than in CML-CP. The
E255V A/T transversion, however, was found in 22 cases of
CML-CP (3.8%), but not in a single case of CML-LBC/Ph+ ALL
(Table S2). We next investigated whether BCR-ABL1 kinase
mutations occurred preferentially at RGYW/WRCY motifs, on
the basis of a previous cytosine deamination quantitative assay,
which determined the ability of 68 cytosine-based DNA motifs to
serve as a substrate for AID (Yu et al., 2004). We found a signifi-
cant correlation between potential AID activity (percentage
in vitro deamination) and BCR-ABL1 mutation frequency in
CML-LBC/Ph+ ALL (r = 0.36; p = 0.01; Figures 6C and 6D;
Figure S6). In contrast, no such correlation was observed for
CML-CP (r = 0.14; p = 0.36; Figure 6E). Importantly, statistical
analyses showed no significant correlation between IC50 values
and AID targeting (r = 0.04; p = 0.84), a feature that argues
against the possibility that our results are biased by selective
advantage of individual mutations (see Figure 6F and Figure S6
for a detailed explanation).
DISCUSSION
We have shown here that the transition from chronic phase CML
into B lymphoid blast crisis is accompanied by expression of
PAX5 and its transcriptional target, the B cell-specific mutator
AID. The presence of hypermutation at MYC, ARF, BCL6, and
the IGHM loci clearly demonstrates the enzymatic activity of
AID in CML-LBC. In like manner, a subset ofBCR-ABL1-induced
mouse leukemia cells express very high levels of AID and carry
deletions and amplifications at an increased frequency relative
to BCR-ABL1-induced leukemia cells from AID/ mice.
The first hint to AID tumorigenic activity was given by studies of
transgenic mice expressing AID constitutively and ubiquitously
under the chicken b-actin promoter (Okazaki et al., 2003). These
animals rapidly succumbed to T cell lymphomas, lung microade-
nomas, and, to a lesser extent, sarcomas, hepatocellular carci-
nomas, and melanomas. Surprisingly, B cell ontogeny was not
directly affected by AID overexpression. Most importantly, B
cell malignancies were not detected in these mice, suggesting
that B lymphocytes might have evolved B cell-specific mecha-
nisms to suppress AID tumorigenic activity (Casellas et al.,
2009). Error-free base excision and mismatch repair pathways,
for instance, correct the vast majority of AID-mediated mutations240 Cancer Cell 16, 232–245, September 8, 2009 ª2009 Elsevier Inoutside the immunoglobulin loci in germinal center B cells (Liu
et al., 2008). Likewise, DNA repair proteins, cell cycle regulators,
and microRNA mir155 prevent AID-induced DNA double-strand
breaks from developing into chromosomal translocations (Dor-
sett et al., 2008). In stark contrast to activated or GC B cells, B
lymphoid AID+ CML-LBC cells fail to up-regulate the full reper-
toire of protective mechanisms that normally accompany AID
activity. This feature, which is likely to be a recurrent theme in
AID+ malignancies, would exacerbate AID-mediated hypermuta-
tion and/or deletion of tumor suppressor genes. On the basis of
these observations, we propose that aberrant activity of AID and
the lack of mechanisms restricting its ability to introduce dele-
tions and chromosomal translocations combine to accelerate
the progression from chronic phase into fatal B lymphoid blast
crisis in patients with CML.
In addition to genomic instability, our data uncovered a corre-
lation between AID expression, the acquisition of BCR-ABL1
kinase domain mutations, and Imatinib resistance in CML-LBC.
This correlation is underscored by the observation that BCR-
ABL1 kinase mutations are at least six times more frequent in
B lymphoid CML-LBC than in myeloid CML-CP (Soverini et al.,
2006; Table S1). Three sets of experiments argue for a causative
role of AID in the acquisition of BCR-ABL1 kinase mutations: (1)
forced expression of AID induces BCR-ABL1 kinase mutations
and Imatinib resistance in human CML cells, (2) forced expres-
sion of PAX5 in CML cells leads to AID gene transcription and
the acquisition of BCR-ABL1 kinase mutations, and (3) AID+/+
but not AID/ mouse BCR-ABL1 leukemias acquire BCR-
ABL1 mutations and Imatinib resistance within a short period
of time. Although BCR-ABL1 mutations do obviously occur in
the absence of AID (e.g., as in some cases of CML-CP), our find-
ings demonstrate that AID dramatically accelerates the acqui-
sition of such mutations and, hence, increases their overall
frequency (e.g., as in CML-LBC; Table S1).
In this context,BCR-ABL1mutations could arise either directly
by way of direct AID-targeted hypermutation, or indirectly as
a result of AID-mediated genetic instability (e.g., by targeting of
genes that are involved in DNA repair). Below we explore these
arguments in detail.
In germinal center B cells, somatic hypermutation occurs
mostly within a 2 kb window downstream of a gene’s transcrip-
tion start site (TSS) and loses its activity exponentially with
increasing distance from this window (Rada and Milstein,c.
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Blast Crisis
(A) The distribution of BCR-ABL1 kinase mutations in CML-CP (n = 572; green), compared with that in Ph+ ALL/LBC (n = 128; red). The x-axis denotes the nucle-
otide position of mutations.
(B) The frequencies of BCR-ABL1 mutations in B lymphoid Ph+ALL/LBC (top) and myeloid CML-CP (bottom) are compared with respect to C/T and G/A
transitions (red). As a quantitative measure of AID-specific mutability, data from a comprehensive AID in vitro deamination assay based on 68 C-based motifs
(Yu et al., 2004) were used. Motifs with AID in vitro activity below 27% and above 59% were considered coldspots and hotspots, respectively.
(C–E) The distribution of BCR-ABL1 kinase mutations in B lymphoid Ph+ALL/LBC (red) and myeloid CML-CP (green) is compared with respect to AID in vitro
activity at the site of mutation (percentage of deamination; based on data from Yu et al., 2004). In (C), the frequency of mutations at AID hotspot and AID coldspot
motifs is compared in Ph+ALL/LBC (red) and myeloid CML-CP (green). A potential correlation between the frequency of BCR-ABL1 mutations and AID-specific
mutability at these sites (percentage of deamination) was tested separately for Ph+ALL/LBC (red; D) and CML-CP (green; E).
(F) The possibility of a potential bias introduced into our analysis is tested: Mutations with a high IC50 for Imatinib confer a high degree of drug resistance and,
hence, a strong selective survival advantage, which may skew the pattern of mutations (e.g., frequency of AID hotspot targeting). For 41 unique mutations, infor-
mation on both IC50 (Imatinib) as well as AID in vitro activity (percentage of deamination; Yu et al., 2004) was available (F). Correlation coefficients (r) and p values
were calculated on the basis of Pearson product moment correlation. Linear regressions and 95% confidence intervals are indicated by black and gray lines,
respectively.2001). Depending on the precise location of the breakpoints
within the BCR and ABL1 genes, the BCR-ABL1 kinase domain
is situated approximately 60 to 75 kb downstream of the
BCR TSS (Figure S1E), a feature that argues against the direct
targeting hypothesis. On the other hand, hypermutation of
immunoglobulin switch domains is known to occur up to 10 kb
downstream of sterile promoters during isotype switching.
Hence, if recruited to an unknown transcription start site down-
stream of the BCR promoter, AID could, in principle, exhibit
enough residual activity to target the BCR-ABL1 kinase domain.
Since manyBCR-ABL1 kinase mutations confer drug resistance,
such lesions will be eventually selected from a heterogeneousCaleukemia cell population even if introduced at extremely low
frequencies. Attempts to uncover hypermutation near the BCR
promoter in CML-LBC cells have been inconclusive so far
(data not shown). A negative result, however, does not neces-
sarily rule out direct targeting of BCL-ABL1 by AID, as hypermu-
tation of a large number of genes in germinal center B cells is
evident only in the absence of error-free repair proteins Msh2
and UNG1 (Liu et al., 2008). Alternatively, AID hypermutation
could be recruited by the QRFP, LOC100131443, or FIBCD1
genes, which are actively transcribed at 5.4 kb, 10.4 kb, and
51.1 kb, respectively, downstream of and in opposite orientation
vis-a`-vis BCR-ABL1 (Figure S1E).ncer Cell 16, 232–245, September 8, 2009 ª2009 Elsevier Inc. 241
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22q11 in close proximity to the human immunoglobulin l locus
(Figure S1E), which strongly recruits AID. The ability of the immu-
noglobulin l locus to recruit AID was further underscored by
the recent identification of a cis-acting Diversification Activator
(DIVAC) element, which induces AID-dependent hypermutation
of both immunoglobulin and nonimmunoglobulin genes in
DT40 chicken B cells (Kothapalli et al., 2008; Blagodatski et al.,
2009; Figure S1E). DIVAC encompasses the immunoglobulin
light chain (IgL) enhancer in chicken, a region that is highly
homologous to the human immunoglobulin l locus (IGLV), which
is located in close proximity to the BCR-ABL1 fusion gene
(Figure S1E). It is conceivable that enhanced transcriptional
activity following the chromosomal break event at 22q11 in
the regional context of both the immunoglobulin l locus and
DIVAC-like elements may lead to recruitment of AID and aberrant
hypermutation of the BCR-ABL1 fusion gene.
Although based on correlative observations, the pattern
of BCR-ABL1 kinase mutations in CML-LBC/Ph+ ALL indeed
suggests direct targeting by AID at a low frequency (Figure 6).
Our data however do not rule out that mechanisms downstream
of or independent from AID are also at play. Genomic instability
resulting from AID-mediated deletion of DNA repair genes would
be an example of the former; the acquisition of random muta-
tions as byproducts of cellular oxidative stress or DNA replica-
tion errors would exemplify the latter. For instance, a recent
mathematical model for drug resistance in CML proposes that
DNA replication errors lead to the acquisition of BCR-ABL1
kinase mutations at a rate of 4 3 107 per cell division (Michor
et al., 2005). This model explains the high frequency of BCR-
ABL1 kinase mutations in CML blast crisis on the basis of the
particularly high proliferation rate of these cells.
CML develops from a hematopoietic stem cell and conse-
quently displays multilineage differentiation potential. During
the chronic phase of the disease, the vast majority (>95%) of
tumor cells differentiate into committed myeloid progenitors,
while a small fraction (<5%) develops into the B lymphoid lineage
likely as a result of PAX5 up-regulation (Takahashi et al., 1998;
Verstegen et al., 1999). In this context, we have shown that
enforced expression of PAX5 promotes B cell lineage conversion
in CML cells and induces aberrant expression of AID. We pro-
pose that this is a key step in the progression from CML-CP to
fatal CML-LBC.
The development of Imatinib resistance in CML-MBC, which
are PAX5 AID (our unpublished observations), argues against
a role of AID in the acquisition of BCR-ABL1 mutations in myeloid
blast crisis. However, CML typically exhibits lineage infidelity,
and in 10% of cases, B/myeloid biphenotypic leukemia cells
give rise to CML blast crisis. By oscillating between myeloid
and B lymphoid phenotypes (Takahashi et al., 1998; Verstegen
et al., 1999), Imatinib-resistant MBC could, in principle, originate
from mutated B lymphoid CML cells that have subsequently lost
their B cell identity. There are several precedents supporting this
view: MYC-driven hematopoietic progenitor cell leukemias are
known to alternate between B lymphoid and myeloid lineages
through spontaneous silencing and reactivation of PAX5-depen-
dent B cell lineage-induction (Yu et al., 2003). Furthermore,
Hodgkin disease represents a prominent example of a human
B cell-derived malignancy that has lost its B cell identity through242 Cancer Cell 16, 232–245, September 8, 2009 ª2009 Elsevier Incaberrant expression of ID2, an inhibitor of PAX5/E2A (Mathas
et al., 2006). Interestingly, we have found that in nearly all cases
of CML-MBC analyzed, IGHM VH-DJH and the Ig k deleting
element (KDE) are rearranged (Figure S7). Rearrangement of
these loci is considered as a permanent imprint of B cell identity
that would be retained even after subsequent myeloid lineage
conversion. Importantly, VH-DJH genes in CML-MBC show
evidence of somatic hypermutation (Figure S7), whereas the
IGHM and KDE loci are unmutated and in germline configuration
in CML-CP. These findings support a B lymphoid origin for at
least some cases of CML-MBC and raise the intriguing possi-
bility that AID activity may promote blast crisis transformation
also in the case of CML-MBC.
EXPERIMENTAL PROCEDURES
Patient Samples and Cell Lines
Normal naive B cells (CD19+ CD27 IgD+) were sorted from peripheral blood
of 12 healthy donors by flow cytometry using a FACSVantage SE cell sorter
(BD Biosciences). Human germinal center B cells (CD77highCD38+IgD) were
isolated from tonsillar resectates (TKH) and sorted by FACS. Bone marrow
samples from patients with CML-CP and early B lymphoid blast crisis CML
(Table S3) were provided from the Departments of Hematology and Oncology,
Charite´ University Hospital Benjamin Franklin, Berlin, Germany (WKH) and the
GIMEMA Study Group/University of Bologna, Bologna, Italy (GM) in compli-
ance with Institutional Review Board regulations (approval from the Ethik-
Kommission of the Charite´, Campus Benjamin Franklin and the IRB of the
University of Southern California Health Sciences Campus and Committee
on Clinical Investigations [CCI] of Childrens Hospital Los Angeles). Informed
consent was obtained from all human subjects. Human CML cell lines (EM2,
JK1, JURL-MK1, K562, KCL22, KYO, LAMA84, and MEG1) and B cell
lymphoma cell lines (Karpas-422, MN60, DB) were obtained from DMSZ,
Braunschweig, Germany.
Aid/ and Aid-GFP-Transgenic Mice, CML Xenograft Model
Aid/ Balb/c mice were derived from Aid/ mice (Muramatsu et al., 2000)
by speed congenic backcrossing and were kindly provided by Dr. Michel
C. Nussenzweig (New York). Aid-GFP reporter-transgenic mice were
described in Crouch et al., 2007. Mice studied in the experiments described
here carried two copies of the Aid-GFP reporter transgene. A detailed descrip-
tion of our CML xenograft model is provided in Supplemental Data. All exper-
iments involving mice conform to the relevant regulatory standards and were
reviewed and approved by Childrens Hospital Los Angeles Institutional Animal
Care and Use Committee (IACUC).
Quantitative RT-PCR
Quantitative real-time PCR carried out with the SYBRGreenER mix from
Invitrogen (Carlsbad, CA) was performed according to standard PCR condi-
tions. During the PCR amplification, the SYBRGreenER dye in the mix binds
to accumulating double-stranded DNA and generates a fluorescence signal
proportional to the DNA concentration that can be visualized and measured
using a ABI7900HT (Applied Biosystems, Foster City, CA) real-time PCR
system. Primers for quantitative RT-PCR are listed in Table S4.
microRNA mir155 Expression in Mouse and Human CML-LBC
Relative to Activated B Cells
Mouse CD43 naive B cells were activated ex vivo in the presence of LPS/IL4
for 72 hr. Human germinal center B cells (CD77highCD38+IgD) were isolated
from tonsil samples by cell sorting. Total RNA was isolated from 106 cells,
and microRNA was processed for Illumina’s deep sequencing using the manu-
facturer’s protocol (Illumina, San Diego, CA). Mature microRNA sequences
(tags) were quantified on the basis of 1 million tags aligned to the mouse
and human microRNome as defined by mirBase (http://microrna.sanger.ac.
uk/sequences/search.shtml)..
Cancer Cell
AID-Induced Blast Crisis Progression in CMLClonality Analysis, Immunoglobulin Spectratyping,
KDE Rearrangement, and Sequence Analysis
PAX5/GFP and GFP-transduced CML and primary CML cells were analyzed
for the presence of IGHM and KDE gene rearrangements (Figure S7) and clon-
ality by spectratyping. To this end, RNA was extracted and subjected to cDNA
synthesis. From cDNAs, VH-DJH gene rearrangements were amplified using
PCR primers specific for VH gene segments together with a primer specific
for the Cm constant region (Table S4). Using a FAM-labeled Cm constant region
gene-specific primer in a run-off reaction, PCR products were labeled and
subsequently analyzed on an ABI3730 DNA analyzer by fragment length anal-
ysis. A normal polyclonal B cell repertoire exhibits a bell-shaped curve of indi-
vidual size-peaks according to a Gaussian-type distribution of length diversity
within the VHDJH junction.
Mutation Analysis and Ligation-Mediated PCR
For mutation analysis ofARF,BCL6, andMYC genes, genomic fragments were
amplified and sequenced using Pyrococcus furiosus DNA polymerase (New
England Biolabs, Ipswich, MA). For each PCR product, both DNA strands
were sequenced, and mutations were counted only if they were found both
in the forward and reverse sequence. PCR primers used for amplification of
ARF, BCL6, and MYC fragments are listed in Table S4. The ABL1 kinase
portion of BCR-ABL1 transcripts was amplified in two rounds of PCR: To
prevent coamplification of normal ABL1 transcripts, the first round of PCR
used BCR-specific (exon 13) and ABL1-specific (exon 9) primers in 10 cycles
of amplification. The second round of amplification (35 cycles) focused on the
ABL1 kinase domain (exons 4–6). The rate of Pfu DNA polymerase errors was
calculated at 4 3 105/ PCR cycle using genomic DNA from MACS-sorted
CD3+ human T cells (immunomagnetic beads from Miltenyi Biotech). A
detailed description of the analysis of DNA single-strand breaks by ligation-
mediated PCR is provided in Supplemental Data.
Western Blotting and Flow Cytometry
Antibodies against human CD19, CD13, CD34, CD38, IgD, VpreB, CD79B
(Igb), IL7Ra, and m-chain; antibodies against mouse CD19, B220, IL7ra, Gr1,
c-kit, Sca-1, and AA4.1; and respective isotype controls were purchased
from BD Biosciences (Heidelberg, Germany). For analysis of AID expression
by flow cytometry, antibodies against AID (rat anti-human AID IgG2b k, clone
EK2 5G9, Cell Signaling Technology, Beverly, MA) were used together with
secondary antibodies (goat anti-rat IgG Cy2, Jackson ImmunoResearch,
West Grove, PA). Prior to staining, cells were fixed with 0.4% paraformalde-
hyde and incubated for 10 min in 90% methanol on ice. For the detection of
AID by Western blot, an antibody against human AID (L7E7; Cell Signaling
Technology), was used together with the WesternBreeze immunodetection
system (Invitrogen, Karlsruhe, Germany). Detection of EIF4E was used as
a loading control (Santa Cruz Biotechnology, Santa Cruz, CA).
Single-Cell RT-PCR Analysis
AID/GFP- or GFP-transduced CML cells were FACS-sorted into 0.5 ml
reaction tubes containing 5 ml of 23 ribonuclease inhibitor mix (2 ml RNasin
[40 u/ml] plus 18 ml, 0.15 mol/l NaCl, 10 mmol/l Tris-HCl [pH 8.0], and 5 mM
DTT). The cells were then quickly frozen on dry ice and stored at 80C. After
one freezing and thawing step, which leads to cell lysis, 10 ml of cell lysates was
added to 50 ml RT-PCR using the Access RT-PCR System (Promega, Madison,
WI). RT-PCR primers for BCR-ABL1, ABL1, or COX6B (Table S4) were used
(50 pmoles each per reaction). To prevent coamplification of normal ABL1
transcripts, the first round of PCR used BCR-specific (exon 13) and
ABL1-specific (exon 9) primers for specific amplification of BCR-ABL1 fusion
transcripts. The second round of amplification focused on the (BCR-) ABL1
kinase domain (exons 4–6). The rate of TaqDNA polymerase errors was calcu-
lated at 2 3 104/ PCR cycle, and PCR products were directly sequenced.
Affymetrix GeneChip Analysis
Bone marrow progenitor cells from AID-GFP reporter transgenic mice were
transformed with a retroviral BCR-ABL1 vector under B lymphoid growth
conditions (IL7). As a control, splenocytes were isolated from AID-GFP
reporter transgenic mice and incubated in the presence of 25 mg/ml LPS
and 10 ng/ml IL4. We sorted AID-GFP+ and AID-GFP cells from BCR-
ABL1-transformed leukemia cells and LPS/IL4-stimulated splenocytes andCsubjected the cells to RNA isolation and microarray analysis using the 430
GeneChip platform (Affymetrix, Santa Clara, CA).
Single Nucleotide Polymorphism Mapping Assay
and Comparative Genomic Hybridization
Genomic DNA was extracted from AIDhigh and AIDlow Ph+ ALL samples and
was subjected to 250K NspI SNP array analysis as described in Supplemental
Data. For comparative genomic hybridization, bone marrow cells from AID/
and AID+/+ mice were transduced with BCR-ABL1. After 9 weeks in cell
culture, genomic DNA was isolated, and amplifications and deletions were
detected using the Mouse Genome CGH Microarray Kit 244A (Agilent Technol-
ogies, Inc., Santa Clara) as described in Supplemental Data.
ACCESSION NUMBERS
Microarray gene expression data, SNP Chip data, and CGH data are available
from GEO. Microarray gene expression data on BCR-ABL1 leukemia cells
from Aid-GFP transgenic bone marrow are available under GEO accession
number GSE13611. SNP array data on 16 AIDhigh and 7 AIDlow cases of Ph+
ALL are available under GEO accession number GSE13612. CGH genome
tiling array data from AID+/+ and AID/BCR-ABL1-transformed leukemia cells
are available under GEO accession number GSE15093.
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